TY - JOUR
T1 - Targeting a Uniquely Nonspecific Prenyl Synthase with Bisphosphonates to Combat Cryptosporidiosis
AU - Artz, Jennifer D.
AU - Dunford, James E.
AU - Arrowood, Michael J.
AU - Dong, Aiping
AU - Chruszcz, Maksymilian
AU - Kavanagh, Kathryn L.
AU - Minor, Wladek
AU - Russell, R. Graham G.
AU - Ebetino, F. Hal
AU - Oppermann, Udo
AU - Hui, Raymond
N1 - Funding Information:
The authors would like to acknowledge the Structural Genomics Consortium (SGC), Jocelyne Lew for the cloning of CpNPPPS, Helen Ren for large scale expression, and Heping Zheng for correcting the Ramachandran outliers of CpNPPPS-ZOL. The BL21(DE3)R3-pRARE2 strain of Escherichia coli used came from Opher Gileadi of the SGC at the University of Oxford. The SGC is a registered charity (# 1097737) that receives funds from the Canadian Institutes for Health Research, the Canadian Foundation for Innovation, Genome Canada through the Ontario Genomics Institute, GlaxoSmithKline, the Knut and Alice Wallenberg Foundation, the Ontario Innovation Trust, the Ontario Ministry for Research and Innovation, Merck & Co. Inc., the Novartis Research Foundation, the Petrus and Augusta Hedlund's Foundation, the Swedish Agency for Innovation Systems, the Swedish Foundation for Strategic Research, and the Wellcome Trust. This research was also supported by funds from the McLaughlin Centre of Molecular Medicine. The methodological part of this work was also supported in part by US NIH grant GM074942.
PY - 2008/12/22
Y1 - 2008/12/22
N2 - Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.
AB - Cryptosporidiosis is a neglected disease without a wholly effective drug. We present a study demonstrating nitrogen-containing bisphosphonates (N-BPs) to be capable of inhibiting Cryptosporidium parvum at low micromolar concentrations in infected MDCK cells. Predictably, the mechanism of action is based on inhibition of biosynthesis of isoprenoids but the target enzyme is unexpectedly a distinctive C. parvum enzyme dubbed nonspecific polyprenyl pyrophosphate synthase (CpNPPPS). This enzyme produces various isoprenoid products larger than FPP and is inhibited by N-BPs at subnanomolar concentrations. It is part of an isoprenoid pathway in Cryptosporidium distinctly different from other organisms. The proposed mechanism of action is corroborated by crystal structures of the enzyme with risedronate and zoledronate bound showing how this enzyme's unique chain length determinant region enables it to accommodate larger substrates and products. These results, combined with existing data on their clinical use, demonstrate that N-BPs are very promising anticryptosporidial drug candidates.
KW - CHEMBIO
KW - MICROBIO
UR - http://www.scopus.com/inward/record.url?scp=57649227299&partnerID=8YFLogxK
U2 - 10.1016/j.chembiol.2008.10.017
DO - 10.1016/j.chembiol.2008.10.017
M3 - Article
C2 - 19101474
AN - SCOPUS:57649227299
SN - 1074-5521
VL - 15
SP - 1296
EP - 1306
JO - Chemistry and Biology
JF - Chemistry and Biology
IS - 12
ER -